Symptoms and General Pathology

All Conditions

Neoplasms

Skin and Connective Tissue Diseases

Facies

Keratosis, Actinic

Keratosis

Keratosis, Seborrheic

Skin Diseases

Precancerous Conditions

Pharmaceutical Solutions

All Drugs and Chemicals

A-101 Solution

Vehicle Solution

Stuart D Shanler, MD

This is a randomized, double-blind, vehicle-controlled, parallel group study.

This is a randomized, double-blind, vehicle-controlled, parallel group study. During this study, the investigator will identify 4 eligible SK Target Lesions on each subject on the trunk, extremities and face.

A Randomized, Double-Blind, Vehicle-Controlled Study in Subjects With Seborrheic Keratosis

A Randomized, Double-Blind, Vehicle-Controlled, PArallel Group Study of the Safety and Effectiveness of A-101 Solution 40% in Subjects With Seborrheic Keratosis on the Trunk, Extremities and Face.

Proportion of subjects for whom all target lesions were judged to be clear on the Physician Lesion Assessment Scale (PLA=0) at Visit 8. The Physician Lesion Assessment Scale is a 4 point scale used by the investigator to assess the subject's target sk lesions.

Proportion of Subjects for whom at least 3 of 4 target lesions were judged to be clear on the Physician Lesion Assessment Scale (PLA=0) at Visit 8

Aclaris Therapeutics, Inc.

A-101 Solution 40% administered once

A-101 Solution

Vehicle Solution administered once

Vehicle Solution: Placebo

Total

Age, Categorical

Age, Continuous

Sex: Female, Male

Ethnicity (NIH/OMB)

Race (NIH/OMB)

United States

Region of Enrollment

Judy Schnyder, Sr. Director Clinical Operations

Proportion of Subjects With All Target Lesions Cleared According to Physician Lesion Assessment Scale

Percent of Lesions Cleared Scale

Overall Study

Spots Global Cancer Trial Database for A Randomized, Double-Blind, Vehicle-Controlled Study in Subjects With Seborrheic Keratosis

Trial Identification

Conditions

Interventions

Study Description

Keywords

Eligibility

Locations

Contact Details

Useful links and downloads for this trial